Canesflor Vaginal Probiotics | Helps Prevent Recurrence of Vaginal Infections such as Thrush | Clinically Proven - 10 Count (Pack of 1)

Product Information

CanesOasis Cystitis Relief 4g granules for oral solution contains sodium citrate. For Thrush: Canesten 100mg Pessary; Canesten 200mg Pessary, contain clotrimazole. Canesten Thrush Combi: Internal & External Creams 10% w/w vaginal cream & 2% w/w cream; Pessary & External Cream 500mg pessary & 2% w/w cream; Soft Gel Pessary & External Cream 500mg vaginal capsule & 2% w/w cream contain clotrimazole. Canesten Thrush: External Cream 2% w/w cream; Internal Cream 10% w/w vaginal cream; Pessary 500mg pessary; Soft Gel Pessary 500mg vaginal capsule contain clotrimazole; Oral Capsule 150mg capsule contains fluconazole. Canesten Thrush Duo Oral Capsule & External Cream 150mg capsule & 2% w/w cream contain fluconazole and clotrimazole. Canesten Athlete’s Foot 1% w/w Cream; Canesten Cream, for fungal infections including nappy rash; Canesten Dermatological Spray, treatment for fungal skin infections, contain clotrimazole. Canesten Hydrocortisone Athlete’s Foot 1%, 1% w/w Cream, Canesten Bifonazole Once Daily Athlete’s Foot 1% w/w Cream contains bifonazole. Canesten Antifungal Cream, contains clotrimazole. Always read the label. Hantoushzadeh, S. et al. Comparative efficacy of probiotic yoghurt and clindamycin in treatment of bacterial vaginosis in pregnant women: a randomized clinical trial. J. Matern Fetal. Neonatal. Med. 25, 1021–1024 (2012). Bradshaw, C. S. et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PLoS One 7, e34540 (2012). Recurrent BV is a common problem associated with the treatment of BV and presents as repeated cases of BV after the initial cessation of symptoms. Available research suggests that recurrent BV may be caused by a relapse of infection due to an inability to reestablish a Lactobacillus-dominated vaginal microbiome or the ineffective suppression of BV-related bacteria 1. Recurrence of BV can also indicate persistent BV, where a positive BV diagnosis remains unchanged after treatment 29, 30. A high rate of BV recurrence after 1 year has been observed, ranging from 50% to 100% depending on the antibiotic used and geographic locations, underscoring the need for additional treatments 1, 23, 30. Other factors that could affect the vaginal microbiome and potentially the efficiency of BV treatment include age (before puberty or after menopause), pregnancy, sexual intercourse, and other diseases or medical conditions 31, 32.

detecting sialidase produced by pathogens associated with the condition [ 49, 50]. Of note, aerobic vaginitis has also been Athanasiou S., Pitsouni E., Antonopoulou S., Zacharakis D., Salvatore S., Falagas M. E., et al.. (2016). The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric 19 ( 5), 512–518. doi: 10.1080/13697137.2016.1212006 Caretto M., Giannini A., Russo E., Simoncini T. (2017). Preventing urinary tract infections after menopause without antibiotics. Maturitas 99, 43–46. doi: 10.1016/j.maturitas.2017.02.004Marrazzo, J. M. et al. Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, Single-blind, Phase 2, controlled trial. Clin. Infect. Dis. 68, 803–809 (2019). Parent, D. et al. Therapy of bacterial vaginosis using exogenously-applied Lactobacilli acidophili and a low dose of estriol: a placebo-controlled multicentric clinical trial. Arzneimittelforschung 46, 68–73 (1996).

Mastromarino, P. et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin. Microbiol Infect. 15, 67–74 (2009). Gambrell R. D., Jr. (1986). The menopause. Invest. Radiol. 21 ( 4), 369–378. doi: 10.1097/00004424-198604000-00017 described in which the vagina is colonized by organisms such as E. coli and enterococci [ 51]. During production might have an effect in vivo. A stable mutant of Lactobacillus salivarius UCC118 that did Duar, R. M. et al. Lifestyles in transition: evolution and natural history of the genus Lactobacillus. FEMS Microbiol. Rev. 41, S27–S48 (2017).Collins S, Beigi R, Mellen C, et al. The effect of pessaries on the vaginal microenvironment. Am J Obstet Gynecol. 2015;212(1):60.e1–60.e6. doi:10.1016/j.ajog.2014.07.024.

Hoffmann, D. E., Palumbo, F. B., Ravel, J., Rowthorn, V. & von Rosenvinge, E. A proposed definition of microbiota transplantation for regulatory purposes. Gut Microbes 8, 208–213 (2017). Pan, M., Hidalgo-Cantabrana, C., Goh, Y. J., Sanozky-Dawes, R. & Barrangou, R. Comparative analysis of Lactobacillus gasseri and Lactobacillus crispatus isolated from human urogenital and gastrointestinal tracts. Front. Microbiol. 10, 3146 (2020). not produce a specific bacteriocin was unable to protect mice against Listeria intestinal infection, while the Pessary-related adverse effects are common, and treatment options are limited. Probiotics may improve pessary-related adverse effects by altering the vaginal microenvironment.

With sequencing information obtained by the human microbiome project and many other vaginal microbiome investigations, we have learned that a large proportion of women without gynecological symptoms have a vaginal microbiome dominated by either L. crispatus or L. iners 2, 3, 4. While an L. crispatus-dominated vaginal microbiome is related to a healthy vaginal condition, L. iners-dominated and specially non- Lactobacillus-dominated vaginal microbiomes are linked to a higher risk for infections, such as human papillomavirus and Chlamydia trachomatis 1, 2. Stapleton, A. E. et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin. Infect. Dis. 52, 1212–1217 (2011).

vaginal douche containing > 1.0 × 10 8 colony-forming units/mL of L. acidophilus ( n = 32), or no treatment Auriemma, R. S. et al. The vaginal microbiome: a long urogenital colonization throughout woman life. Front. Cell Infect. Microbiol. 11, 686167 (2021). Tachedjian, G., O’Hanlon, D. E. & Ravel, J. The implausible ‘in vivo’ role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota. Microbiome 6, 29 (2018). Das S., Bhattacharjee M. J., Mukherjee A. K., Khan M. R. (2022). Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics. Crit. Rev. Microbiol. 21, 1–27. doi: 10.1080/1040841x.2022.2049696Anderson D. J., Marathe J., Pudney J. (2014). The structure of the human vaginal stratum corneum and its role in immune defense. Am. J. Reprod. Immunol. 71 ( 6), 618–623. doi: 10.1111/aji.12230 Uehara, S. et al. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J. Antimicrob. Agents 28, 30–34 (2006). Muzny, C. A. et al. An updated conceptual model on the pathogenesis of bacterial vaginosis. J. Infect. Dis. 220, 1399–1405 (2019).